Q3 2022 Results

Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis submission schedule Supplementary indications for existing brands EXISTING BRANDS Appendix Innovation: Clinical trials References Abbreviations 2022 2023 2024 2025 ≥2026 Cosentyx secukinumab, AIN457 LCM Cosentyx LCM aflibercept BioS Beovu LCM Atectura LCM Kesimpta³ LCM Piqray LCM secukinumab, AIN457 SOK583 PSA IV axSpA IV Ophthalmology indication (as originator) brolucizumab, RTH258 Diabetic retinopathy indacaterol + mometasone, QMF149 Asthma, pediatrics ofatumumab Multiple sclerosis, pediatrics Cosentyx LCM denosumab BioS Adakveo LCM Cosentyx LCM Aimovig LCM Leqvio LCM secukinumab, AIN457 GP2411 SEG101 secukinumab, AIN457 erenumab, AMG334 KJX839 alpelisib, BYL719 TNBC Rydapt midostaurin, PKC412 LCM Hidradenitis suppurativa Osteoporosis (same as originator) Sickle cell disease, pediatrics. GCA Pediatric Migraine CVRR-LDLC Acute myeloid leukemia, pediatrics Entresto EU¹ LCM Kisqali LCM Coartem LCM Leqvio LCM Cosentyx LCM Mayzent³ LCM sacubitril/valsartan, LCZ696 ribociclib, LEE011 Pediatric CHF HR+/HER2- BC (adj) artemether + lumefantrine, COA566 Malaria uncompl., formula for <5kg KJX839 secukinumab, AIN457 siponimod, BAF312 Ped Hyperlipidemia Lupus Nephritis Multiple sclerosis, pediatrics Tafinlar + Mekinist LCM Lutathera LCM Jakavi LCM Piqray LCM dabrafenib + trametinib, DRB436 177Lu-oxodotreotide² ruxolitinib, INC424 alpelisib, BYL719 HGG/LGG Pediatrics GEP-NET 1L G3 Pediatrics Acute GVHD HER2+ adv BC Xolair omalizumab, IGE025 LCM Piqray LCM Jakavi LCM Promacta LCM alpelisib, BYL719 ruxolitinib, INC424 eltrombopag, ETB115 Auto-injector Ovarian cancer Pediatrics Chronic GVHD Radiation sickness syndrome Xolair LCM Zolgensma LCM omalizumab, IGE025 AVXS-101 OAV101 Food allergy SMA IT 1. Approved in US. 2. 177Lu-dotatate in US. 42 Investor Relations | Q3 2022 Results 3. Kesimpta and Mayzent: pediatric study in multiple sclerosis run in conjunction (NEOS). NOVARTIS | Reimagining Medicine

View entire presentation